Examining Applications of Neural Networks in Predicting Polygenic Traits

Total Page:16

File Type:pdf, Size:1020Kb

Examining Applications of Neural Networks in Predicting Polygenic Traits Examining applications of Neural Networks in predicting polygenic traits McMaster University Mu Tian Date Abstract Polygenic risk scores are scores used in precision medicine in order to assess an individual's risk of having a certain quantitative trait based on his or her genetics. Previous works have shown that machine learning, namely Gradient Boosted Regression Trees, can be successfully applied to calibrate the weights of the risk score to improve its predictive power in a target population. Neural networks are a very powerful class of machine learning algorithms that have demonstrated success in various fields of genetics, and in this work, we examined the predictive power of a polygenic risk score that uses neural networks to perform the weight calibration. Using a single neural network, we were able to obtain prediction R2 of 0.234 and 0.074 for height and BMI, respectively. We further experimented with changing the dimension of the input features, using ensembled models, and varying the number of splits used to train the models in order to obtain a final prediction R2 of 0.242 for height and 0.0804 for BMI, achieving a relative improvement of 1.26% in prediction R2 for height. Furthermore, we performed extensive analysis of the behaviour of the neural network-calibrated weights. In our analysis, we highlighted several potential drawbacks of using neural networks, as well as machine learning algorithms in general when performing the weight calibration, and offer several suggestions for improving the consistency and performance of machine learning-calibrated weights for future research. i Acknowledgements First and foremost, I want to thank my amazing girlfriend Margaret for being so supportive throughout the entire research process. Secondly, I want to thank my supervisor, Dr. Canty, for all the support and insights offered over the course of the research, Dr. Par´eand Shihong Mao for the the assistance in setting up the experiments, as well as Dr. Bolker for being a part of the defense committee. ii Contents 1 Introduction 1 1.1 Background and definitions . .2 1.2 Genome Wide Association Study . .3 1.3 Applications of GWAS . .4 2 Polygenic Risk Score 6 2.1 Pruning and Thresholding . .7 2.2 Applications of Polygenic Risk Scores . .8 2.3 Penalized Regression Models . 10 2.4 LDpred . 12 2.5 Machine Learning in Predicting Polygenic Traits . 14 2.6 A Neural Network approach to calibrating weights . 17 3 Neural Networks - Background 18 3.1 Structure . 18 3.2 Perceptron . 20 3.3 Model Training . 21 3.4 Optimizing neural networks . 22 3.5 Batch Training . 23 3.6 Adaptive Optimizers . 24 3.7 Model Initialization . 25 3.8 Neural Network Regularization . 25 3.9 Learning Rate Scheduling . 28 iii 3.10 Gradient Clipping . 29 3.11 Neural Networks in Genetics . 29 4 Data and Experiments 33 4.1 Data . 33 4.2 Model Fitting . 35 4.3 Error Report . 37 4.4 Further Model Improvements . 41 4.5 Model Fitting with Additional Data . 46 4.5.1 Analysis of Increased Variance in Neural Networks . 48 4.6 Model Ensembling . 50 4.6.1 Effects of Ensembled Models on Variability ofw ^ .............. 52 4.7 Summary of Results . 53 5 Further Analysis of Fitted Models 55 5.1 Distinct Clusters ofw ^ ................................ 55 ^ 5.2 Effect of βext = 0 in the PRS . 60 5.3 Difference in Variability in Height and BMI . 66 5.4 Effect of Different Splits on the PRS . 69 5.5 Using no Splits of the Data to train the NN . 74 5.6 Interpretability of Neural Networks . 77 5.7 Issues With Relying on an External GWAS . 78 6 Conclusion and Future Directions for Research 79 6.1 Conclusion . 79 6.2 Further Model Ensembling . 80 6.3 Novel Model Architectures . 81 6.4 Convolutional and Recurrent Neural Networks . 83 6.5 Sequence to Sequence Networks . 84 A Appendix 86 A.1 Common Activation Functions . 86 iv A.2 Common Loss Functions . 86 A.3 Optimization Algorithms . 87 A.4 Batch Normalization Algorithm . 88 A.5 Batch Normalization Backpropagation . 89 A.6 How Model Averaging Reduces Variance . 93 v List of Figures 3.1 Simple Neural Network Diagram . 19 3.2 Perceptron diagram . 20 ^ 4.1 Plot of βext for height and BMI . 34 ^ 4.2 Plot ofw ^ against βext for both height and BMI under the incorrect formula . 38 ^ 4.3 Plot ofw ^ against βext for both height and BMI under the correct formula . 39 4.4 Plot of training and validation loss for height . 42 4.5 Plot of training and validation loss for BMI . 43 4.6 Mean and standard deviation ofw ^ (stage 1 features) . 49 4.7 Mean and standard deviation ofw ^ (univariate features) . 49 4.8 Mean and standard deviation ofw ^ across 5 ensembled models . 53 5.1 Plot of mean vs standard deviation of each set ofw ^ for height across 20 runs . 56 5.2 Plot of mean vs standard deviation of each set ofw ^ for BMI across 20 runs . 58 5.3 Box plot of each distinct set's mean across 20 runs of the experiment . 59 5.4 Box plot of each distinct set's standard deviation across 20 runs of the experiment 59 5.5 Plot of Mean vs Standard Deviation of each set ofw ^ for height across 20 runs ^ after removing the weights where βext =0 ..................... 61 5.6 Plot of Mean vs Standard Deviation of each set ofw ^ for BMI across 20 runs after ^ removing the weights where βext =0 ........................ 62 5.7 Histogram of 0's in the LD adjustment window . 65 ^ 5.8 Box plot of βext across splits . 67 ^ 5.9 Plot of βext against standard deviation of acrossw ^ 20 runs of the experiment . 68 5.10 Plot of d against d^ (Single Model) . 70 vi 5.11 Plot of d against d^ (Ensemble) . 70 5.12 Plot of d against d^ (2 Splits) . 71 5.13 Plot of d against d^ (10 Splits) . 72 5.14 Plot of d against d^ using GBRT . 73 5.15 Plot of d against d^ (No Splits) . 75 5.16 Plot of mean against sd ofw ^ across 20 runs (No Splits) . 76 vii List of Tables 4.1 Initial test results of R2 under different model architectures . 37 4.2 R2 Values of PRS using different NN architectures and correctw ^ formula . 40 4.3 R2 Values of PRS under different training times . 41 4.4 Training MSE for the 1-Layer NN . 42 4.5 R2 Values of PRS under different optimizers . 44 4.6 R2 Values of different PRS without LD adjustment . 45 4.7 R2 Values of different PRS with LD adjustment . 45 4.8 R2 Values of neural networks with extra features . 47 4.9 R2 Values of different PRS generated by Ensembles after LD adjustment . 51 4.10 R2 Values of different PRS compared to machine learning adjusted PRS . 53 5.1 R2 Values of PRS generated by the neural network trained without 0's . 64 5.2 R2 Values of different PRS generated by the neural network with different splits of the data . 73 5.3 R2 Values of different PRS generated by the neural network with no splits . 75 viii Chapter 1 Introduction Polygenic risk scores are scores used to assess an individual's risk of having a certain quanti- tative trait based on his or her genetics, and are widely used in precision medicine. Currently, a polygenic risk score is built from regression coefficients from an external genome wide asso- ciation study (GWAS), sometimes, some type of adjustment is used to calibrate the risk score and to improve its predictive power. Machine learning is a widely popular set of computational methods aimed at solving big data problems, which have shown some promising results in cal- ibrating polygenic risk scores to improve their predictive potential. Par´eet al. (2017) showed that by using Gradient Boosted Regression Trees (GBRT) to adjust the weights of the poly- genic risk score, they were able to achieve an improvement in R2 over currently used methods of computing the polygenic risk score. While Par´eet al. (2017) achieved improved results in prediction R2, over other methods, we hypothesize that it may be possible to further improve upon their results. Gradient boosting is a powerful class of machine learning algorithms, but with recent advances in deep learning, neural networks (NN) have the capability to achieve comparable, sometimes exceeding the pre- dictive power of gradient boosted trees (De Br´ebissonet al., 2015; Guo and Berkhahn, 2016). In this work, we examine and compare the performance of a neural network calibrated polygenic risk score that incorporates recent advances and current best practices in the field. 1 1.1 Background and definitions The study of genetics begins with the DNA. Deoxyribonucleic acid (DNA) is a molecule, found typically in the nucleus of a cell which carries the genetic information of the living organism. The genetic information stored in the DNA codes for cellular growth, function, and reproduc- tion. DNA is made up of two strands of molecules called nucleotides coiled together to form a double helix structure. Each nucleotide is made up of one of the four types of nitrogen bases: adenine (A), thymine (T), guanine (G), and cytosine (C), combined with a sugar molecule and phosphate molecule. Due to the Watson-Crick pairing rules, which states that only adenine can be paired with thymine, and guanine with cytosine, each strand of the DNA contains the exact same genetic information, with different coding. A sequence of DNA that produces a protein or other functional element is referred to as a gene.
Recommended publications
  • Identifying Intergenerational Risk Factors for ADHD Symptoms Using Polygenic Scores in the Norwegian Mother, Father and Child Cohort
    medRxiv preprint doi: https://doi.org/10.1101/2021.02.16.21251737; this version posted February 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Intergenerational transmission of ADHD Identifying intergenerational risk factors for ADHD symptoms using polygenic scores in the Norwegian Mother, Father and Child Cohort Jean-Baptiste Pingault1,2*, Wikus Barkhuizen1*, Biyao Wang1, Laurie J. Hannigan3,4, Espen Moen Eilertsen6, Ole A. Andreassen7, Helga Ask5, Martin Tesli5,7, Ragna Bugge Askeland4,5, George Davey Smith4,9, Neil Davies4,8,9, Ted Reichborn-Kjennerud5, †Eivind Ystrom5,6, †Alexandra Havdahl3,5,6 *Equal first authors †Equal last authors 1 Division of Psychology and Language Sciences, University College London, London, United Kingdom 2 MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College, London, United Kingdom 3 Nic Waals Institute, Lovisenberg Diaconal Hospital, Oslo, Norway 4 Medical Research Council Integrative Epidemiology Unit, University of Bristol, BS8 2BN, United Kingdom 5 Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway 6 PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway 7 NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway 8 K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Norway 9 Population Health Sciences, Bristol Medical School, University of Bristol, Barley House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom Address correspondence to Dr.
    [Show full text]
  • Common Genetic Variation and Schizophrenia Polygenic Risk
    RESEARCH ARTICLE Neuropsychiatric Genetics Common Genetic Variation and Schizophrenia Polygenic Risk Influence Neurocognitive Performance in Young Adulthood Alex Hatzimanolis,1 Pallav Bhatnagar,2 Anna Moes,2 Ruihua Wang,1 Panos Roussos,3,4 Panos Bitsios,5 Costas N. Stefanis,6 Ann E. Pulver,1 Dan E. Arking,2 Nikolaos Smyrnis,6,7 Nicholas C. Stefanis,6,7 and Dimitrios Avramopoulos1,2* 1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 2McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 3Department of Psychiatry, Friedman Brain Institute and Department of Genetics and Genomics Science, Institute of Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 4James J. Peters Veterans Affairs Medical Center, Bronx, New York, New York 5Department of Psychiatry and Behavioral Sciences, Faculty of Medicine, University of Crete, Heraklion, Greece 6University Mental Health Research Institute, Athens, Greece 7Department of Psychiatry, Eginition Hospital, University of Athens Medical School, Athens, Greece Manuscript Received: 3 December 2014; Manuscript Accepted: 29 April 2015 Neurocognitive abilities constitute complex traits with consid- erable heritability. Impaired neurocognition is typically ob- How to Cite this Article: served in schizophrenia (SZ), whereas convergent evidence Hatzimanolis A, Bhatnagar P, Moes A, has shown shared genetic determinants between neurocognition Wang R, Roussos P, Bitsios P, Stefanis CN, and SZ. Here, we report a genome-wide association study Pulver AE, Arking DE, Smyrnis N, Stefanis (GWAS) on neuropsychological and oculomotor traits, linked NC, Avramopoulos D. 2015. Common to SZ, in a general population sample of healthy young males Genetic Variation and Schizophrenia ¼ (n 1079).
    [Show full text]
  • Polygenic Methods and Their Application to Psychiatric Traits
    This is the peer reviewed version of the following article: Wray, N. R., & Visscher, P. M. (2015). Quantitative genetics of disease traits. Wray, N. R., Lee, S. H., Mehta, D., Vinkhuyzen, A. A., Dudbridge, F., & Middeldorp, C. M. (2014). Research review: polygenic methods and their application to psychiatric traits. Journal of Child Psychology and Psychiatry, 55(10), 1068–1087. DOI: 10.1111/jcpp.12295 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving. Polygenic methods and their application to psychiatric traits Naomi R Wray1*, S Hong Lee1, Divya Mehta1, Anna AE Vinkhuyzen1, Frank Dudbridge2, Christel M Middeldorp3,4 1. The University of Queensland, Queensland Brain Institute, Queensland, Australia 4068 2. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK 3. Department of Biological Psychology, Neuroscience Campus Amsterdam, VU University Amsterdam, The Netherlands 4. Department of Child and Adolescent Psychiatry, GGZ inGeest/VU University Medical Center, Amsterdam, The Netherlands * Corresponding author. [email protected] Abstract Background Despite evidence from twin and family studies for an important contribution of genetic factors to both childhood and adult onset psychiatric disorders, identifying robustly associated specific DNA variants has proved challenging. In the pre-genomics era the genetic architecture (number, frequency and effect size of risk variants) of complex genetic disorders was unknown. Empirical evidence for the genetic architecture of psychiatric disorders is emerging from the genetic studies of the last five years. Methods and scope We review the methods investigating the polygenic nature of complex disorders.
    [Show full text]
  • The BRCA1 Tumor Suppressor
    Journal of Translational Science Review Article ISSN: 2059-268X The BRCA1 tumor suppressor: potential long-range interactions of the BRCA1 promoter and the risk of breast cancer Beata Anna Bielinska* Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland Abstract Breast cancer is a complex disease with different phenotypes associated with genetic and non-genetic risk factors. An aberrant expression of the BRCA1 tumor suppressor as well as dysfunction of BRCA1 protein caused by germline mutations are implicated in breast cancer aethiology. BRCA1 plays a crucial role in genome and epigenome stability. Its expression is auto regulated and modulated by various cellular signals including metabolic status, hypoxia, DNA damage, estrogen stimulation. The review describes breast cancer risk factors, the BRCA1 gene expression and functions as well as covers the role of long-range genomic interactions, which emerge as regulators of gene expression and moderators of genomic communication. The potential long-range interactions of the BRCA1 promoter (driven by polymorphic variant rs11655505 C/T, as an example) and their possible impact on the BRCA1 gene regulation and breast cancer risk are also discussed. Introduction efficiency of BRCA1 transcription [9]. However, to date the mechanism underlying effect of the BRCA1 promoter variant rs11655505 C>T Female breast cancer is one of the most common cancers worldwide remains unknown. with app.1.68 million cases diagnosed annually [1]. It is a complex disease characterized by molecular and phenotypic heterogeneity Besides high risk BRCA1/BRCA2 mutations, moderate risk observed both within populations and intra-individually, within mutations such as those found in DNA repair genes (CHEK2, ATM, single tumor cells in a spatiotemporal manner, as pointed out by PALB2) also demonstrate familial clustering.
    [Show full text]
  • Within-Sibship GWAS Improve Estimates of Direct Genetic Effects
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.05.433935; this version posted March 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Within-sibship GWAS improve estimates of direct genetic effects Laurence J Howe1,2 *, Michel G Nivard3, Tim T Morris1,2, Ailin F Hansen4, Humaira Rasheed4, Yoonsu Cho1,2, Geetha Chittoor5, Penelope A Lind6,7,8, Teemu Palviainen9, Matthijs D van der Zee3, Rosa Cheesman10,11, Massimo Mangino12,13, Yunzhang Wang14, Shuai Li15,16,17, Lucija Klaric18, Scott M Ratliff19, Lawrence F Bielak19, Marianne Nygaard20,21, Chandra A Reynolds22, Jared V Balbona23,24, Christopher R Bauer25,26, Dorret I Boomsma3,27, Aris Baras28, Archie Campbell29, Harry Campbell30, Zhengming Chen31,32, Paraskevi Christofidou12, Christina C Dahm33, Deepika R Dokuru23,24, Luke M Evans24,34, Eco JC de Geus3,35, Sudheer Giddaluru36,37, Scott D Gordon38, K. Paige Harden39, Alexandra Havdahl40,41, W. David Hill42,43, Shona M Kerr18, Yongkang Kim24, Hyeokmoon Kweon44, Antti Latvala9,45, Liming Li46, Kuang Lin31, Pekka Martikainen47,48,49, Patrik KE Magnusson14, Melinda C Mills50, Deborah A Lawlor1,2,51, John D Overton27, Nancy L Pedersen14, David J Porteous25, Jeffrey Reid28, Karri Silventoinen47, Melissa C Southey17,52,53, Travis T Mallard39, Elliot M Tucker-Drob39, Margaret J Wright54, Social Science Genetic Association Consortium, Within Family
    [Show full text]
  • LDL Polygenic Risk Scores in Practice
    University of Copenhagen & Copenhagen University Hospital LDL polygenic risk scores in practice Anne Tybjærg-Hansen MD DMSc Professor, Chief Physician Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark FH Global Summit, Atlanta 211019 Outline • Introduction to polygenic risk score • Polygenic risk scores for LDL cholesterol and FH • Polygenic risk scores for CAD and FH – polygenic versus omnigenic scores • Take home message Introduction to polygenic risk score Genome-wide association study of LDL cholesterol (from GLGC) P<10-8 Willer CJ et al. Nat Genet 2013 Creating a polygenic score GWAS SNPs Individually: tiny effects ComBined: larger effect Effect of gene score on trait level 1.0 1.2 Odds ratio Genome-wide association study of LDL cholesterol Polygenic risk score P<10-8 Willer CJ et al. Nat Genet 2013 Genome-wide association studies (GWAS’) for lipids In sufficiently large samples, many ~ 100,000 previously non-significant loci would European ancestry become nominally significant, 95 loci although effect sizes are close to zero. ~ 600,000 ~85,000 non-Europeans ~200,000 >118 novel loci 7,898 non-Europeans (~268 known loci) 62 novel loci 30.4 mill SNPs Klarin et al. 2010 2013 2018 Polygenic risk scores for LDL cholesterol and Familial Hypercholesterolemia Rigshospitalet The Centre of Diagnostic Investigations Diagnostic criteria for FH 1/220 individuals • Definite FH: > 8 points • Probable FH: 6-8 points • Possible FH: 3-5 points • Unlikely FH: 0-2 points Mette Christoffersen 9 Rigshospitalet The Centre of Diagnostic Investigations Clinical vs. mutation diagnosis Polygenic cause? 20-40% High Lp(a)? 60-80 % Polygenic cause? Modified from Eur Heart J.
    [Show full text]
  • Selection Against Variants in the Genome Associated PNAS PLUS with Educational Attainment
    Selection against variants in the genome associated PNAS PLUS with educational attainment Augustine Konga,b,1, Michael L. Friggea, Gudmar Thorleifssona, Hreinn Stefanssona, Alexander I. Youngc, Florian Zinka, Gudrun A. Jonsdottira, Aysu Okbayd,e, Patrick Sulema, Gisli Massona, Daniel F. Gudbjartssona,b, Agnar Helgasona,f, Gyda Bjornsdottira, Unnur Thorsteinsdottira,g, and Kari Stefanssona,g,1 adeCODE genetics/Amgen Inc., Reykjavik 101, Iceland; bSchool of Engineering and Natural Sciences, University of Iceland, Reykjavik 101, Iceland; cWellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom; dDepartment of Applied Economics, Erasmus School of Applied Economics, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands; eInstitute for Behavior and Biology, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands; fDepartment of Anthropology, University of Iceland, Reykjavik 101, Iceland; and gFaculty of Medicine, University of Iceland, Reykjavik 101, Iceland Edited by Andrew G. Clark, Cornell University, Ithaca, NY, and approved December 5, 2016 (received for review July 22, 2016) Epidemiological and genetic association studies show that genet- 62 cohorts were used to determine the weightings for POLYEDU. ics play an important role in the attainment of education. Here, we We computed POLYEDU for over 150,000 Icelanders who were investigate the effect of this genetic component on the reproduc- directly genotyped with chip arrays and imputed for additional tive history of 109,120 Icelanders and the consequent impact on sequence variants discovered through whole-genome sequencing the gene pool over time. We show that an educational attainment of 8,453 Icelanders (20) (Materials and Methods). POLYEDU was polygenic score, POLYEDU, constructed from results of a recent scaled to an SD of 1, hereafter referred to as standard units (SUs).
    [Show full text]
  • Clinical Use of Current Polygenic Risk Scores May Exacerbate Health Disparities
    PERSPECTIVE https://doi.org/10.1038/s41588-019-0379-x Clinical use of current polygenic risk scores may exacerbate health disparities Alicia R. Martin 1,2,3*, Masahiro Kanai 1,2,3,4,5, Yoichiro Kamatani 5,6, Yukinori Okada 5,7,8, Benjamin M. Neale 1,2,3 and Mark J. Daly 1,2,3,9 Polygenic risk scores (PRS) are poised to improve biomedical outcomes via precision medicine. However, the major ethical and scientific challenge surrounding clinical implementation of PRS is that those available today are several times more accurate in individuals of European ancestry than other ancestries. This disparity is an inescapable consequence of Eurocentric biases in genome-wide association studies, thus highlighting that—unlike clinical biomarkers and prescription drugs, which may indi- vidually work better in some populations but do not ubiquitously perform far better in European populations—clinical uses of PRS today would systematically afford greater improvement for European-descent populations. Early diversifying efforts show promise in leveling this vast imbalance, even when non-European sample sizes are considerably smaller than the largest studies to date. To realize the full and equitable potential of PRS, greater diversity must be prioritized in genetic studies, and summary statistics must be publically disseminated to ensure that health disparities are not increased for those individuals already most underserved. RS, which predict complex traits on the basis of genetic All studies to date using well-powered genome-wide association data, are of burgeoning interest to the clinical community, as studies (GWAS) to assess the predictive value of PRS across a range Presearchers demonstrate their growing power to improve clini- of traits and populations have made a consistent observation: PRS cal care, genetic studies of a wide range of phenotypes increase in predict individual risk far more accurately in Europeans than non- size and power, and genotyping costs plummet to less than US$50.
    [Show full text]
  • Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer Louis Lello1, Timothy G
    www.nature.com/scientificreports Corrected: Author Correction OPEN Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer Louis Lello1, Timothy G. Raben1, Soke Yuen Yong1, Laurent C. A. M. Tellier2,3 & Stephen D. H. Hsu1,2,3 We construct risk predictors using polygenic scores (PGS) computed from common Single Nucleotide Polymorphisms (SNPs) for a number of complex disease conditions, using L1-penalized regression (also known as LASSO) on case-control data from UK Biobank. Among the disease conditions studied are Hypothyroidism, (Resistant) Hypertension, Type 1 and 2 Diabetes, Breast Cancer, Prostate Cancer, Testicular Cancer, Gallstones, Glaucoma, Gout, Atrial Fibrillation, High Cholesterol, Asthma, Basal Cell Carcinoma, Malignant Melanoma, and Heart Attack. We obtain values for the area under the receiver operating characteristic curves (AUC) in the range ~0.58–0.71 using SNP data alone. Substantially higher predictor AUCs are obtained when incorporating additional variables such as age and sex. Some SNP predictors alone are sufcient to identify outliers (e.g., in the 99th percentile of polygenic score, or PGS) with 3–8 times higher risk than typical individuals. We validate predictors out-of-sample using the eMERGE dataset, and also with diferent ancestry subgroups within the UK Biobank population. Our results indicate that substantial improvements in predictive power are attainable using training sets with larger case populations. We anticipate rapid improvement in genomic prediction as more case- control data become available for analysis. Many important disease conditions are known to be signifcantly heritable1. Tis means that genomic predictors and risk estimates for a large number of diseases can be constructed if enough case-control data is available.
    [Show full text]
  • Genetic Risk Score Based on Statistical Learning Florian Prive
    Genetic risk score based on statistical learning Florian Prive To cite this version: Florian Prive. Genetic risk score based on statistical learning. Bioinformatics [q-bio.QM]. Université Grenoble Alpes, 2019. English. NNT : 2019GREAS024. tel-02476202 HAL Id: tel-02476202 https://tel.archives-ouvertes.fr/tel-02476202 Submitted on 12 Feb 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 THÈSE Pour obtenir le grade de DOCTEUR DE LA COMMUNAUTE UNIVERSITE GRENOBLE ALPES Spécialité : MBS - Modèles, méthodes et algorithmes en biologie, santé et environnement Arrêté ministériel : 25 mai 2016 Présentée par Florian PRIVÉ Thèse dirigée par Michael BLUM, Directeur de recherche CNRS, Université Grenoble Alpes, et co-encadrée par Hugues ASCHARD, chercheur Institut Pasteur préparée au sein du Laboratoire Techniques de L'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications. dans l’École Doctorale Ingénierie pour la santé la Cognition et l'Environnement Score de risque génétique utilisant de l'apprentissage statistique. Genetic
    [Show full text]
  • A Complex Trait Genomics Approach to Investigating Amyotrophic Lateral Sclerosis
    A Complex Trait Genomics Approach to Investigating Amyotrophic Lateral Sclerosis Restuadi Bachelor of Science, Master of Bioinformatics (Advanced) https://orcid.org/0000-0001-8434-4465 A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2020 Institute For Molecular Bioscience 2 Abstract Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). It is a fatal neurodegenerative disease that has a lifetime risk of 1 in 300 people worldwide, with death often occurring within 3 to 5 years from the onset of symptoms. Currently, there is no effective treatment and no cure for ALS, in part due to a limited understanding of its aetiology. Most ALS genetics research to date is driven by discoveries in the familial form of the disease, where causality seems to reflect a heritable single gene mutation. Only a small proportion of ALS research is focussed on investigating the cause of sporadic ALS, which is likely to be a complex genetic disorder with many factors contributing to its aetiology, including genetic and environmental risk factors. The traditional ALS genetic research approaches which only rely on familial data or the single-trait Genome Wide Association Study (GWAS) paradigm might not be ideal for studying complex disorders like ALS. Therefore, the research presented in this thesis aims to study the aetiology of ALS using statistical techniques that have been developed for genetic analysis of complex traits applied to publicly available summary statistics level GWAS and multi-omics data. Newly available gut microbiome data was also used to understand non-genetic factors on the development of disease.
    [Show full text]
  • An Epigenome-Wide Association Study Meta-Analysis of Educational Attainment
    Supplementary note to accompany An epigenome-wide association study meta-analysis of educational attainment 1 Study overview ................................................................................................................... 3 1.1 Sample inclusion criteria ........................................................................................................ 3 1.2 Phenotype definition and sample descriptive statistics ........................................................ 4 1.3 DNA methylation measurement and cohort-level quality control (QC) ............................ 4 2 Epigenome-wide association study (EWAS) ................................................................... 6 2.1.1 Control variables in the adjusted model .............................................................................. 6 2.1.2 Cohort-specific control variables ........................................................................................ 7 2.2 Description of major steps in meta-level quality-control (QC) analyses ............................ 7 2.3 Meta-analysis ........................................................................................................................... 7 2.4 Results – Epigenome-wide association study ........................................................................ 8 2.4.1 Quality control results ......................................................................................................... 8 2.4.1 EWAS results .....................................................................................................................
    [Show full text]